



ISSUE 27 | DEC 2025

REMAP-CAP

IN THIS ISSUE

- Welcome
- Achievements 2025
- Core Protocol V4.0 Training
- eCRF Update
- Baloxavir & Tocilizumab
- Corticosteroid Survey

Dear REMAP-CAP family,

As winter has started, lots of activities are ongoing in the trial. A big milestone is the release of the updated eCRF. We've made it much 'leaner' and have incorporated changes needed for the updated Core Protocol (v4.0). We hope you'll find it easier and faster to complete. We're also developing new corticosteroid interventions in the trial, and your input on what the most important questions are is needed, to ensure we choose interventions that matter to all of us. Apart from all the activities, december is also a time to look back and look forward. Looking back, I am incredibly proud of our achievements this year (read about them in this newsletter). I wish you all happy holidays, some well-deserved time off, and I am looking forward to working with you in 2026, both in REMAP-CAP and as CEO of Ecraid.

Lennie

Achievements 2025

Thank you to all participating sites and local teams for your hard work. We are proud of the achievements made in 2025:

- 405 patients enrolled resulting in 597 patient randomisations (as of 15-Dec-25);
- Submission and approval of Core Protocol V4 and associated documents;
- Contract with Roche signed, Tocilizumab and Baloxavir available in EU Depot for Influenza Antiviral and Influenza Immune Modulation domains;
- Successful closure of the MHRA Sponsor and site inspections as well as the Infarmed site inspection;
- 2 primary publications;
- Kick-off IMPRINT in NL;
- Adding new sites to the REMAP-CAP family.

Core Protocol V4.0 Training

We have started the transition from Core Protocol Version 3.0 to Core Protocol Version 4.0. For this, the first central Core V4.0 transition training took place on 10th December 2025. Big thanks for all attendees who were present during this first session. A second central training will take place on 8th January 2026. If you have not received an invitation, you can contact your CRA or country manager. Recordings of the central training will become available, which can be used for self-training if you could not attend the meeting. The recording will be shared with all sites shortly.

Top 3 recruiting sites since October 1st

1. South Tyneside District Hospital (UK)
2. Sunderland Royal Hospital (UK)
3. St. Thomas Hospital (UK)

Ecraid news

Ecraid is pleased to announce the appointment of Lennie Derde as its new Chief Executive Officer, effective 1 January 2026. She will succeed Ecraid's co-founder Prof. Marc Bonten.

eCRF Update

On November 24th, the new database for Core Protocol V4.0 was launched. The URL to the eCRF remains the same. You can now access both the previous and the updated systems using the "Switch system" button, which is available on the dashboard visible after log in.

The updated eCRF allows you to view patients recruited or to be recruited under Core V3.0. Once your site is activated for Core V4.0, all subsequent participants will automatically be randomized in the new eCRF.

If you have any questions or encounter any issues, please feel free to contact us.

Baloxavir & Tocilizumab

Baloxavir and Tocilizumab, which are provided by Roche for the Influenza Antiviral and Influenza Immune Modulation DSAs, are now available in the EU Depot. Interested sites need documented training on the new interventions and the IMP order process. Your CRA or country manager will be in contact with you and can provide all information and documents needed for start-up.

Corticosteroid Survey

Last November, we distributed a survey regarding the use of corticosteroids. For those who have already responded: thank you—your input is greatly appreciated.

The information collected is highly valuable, we would like to kindly remind those who have not yet completed the survey to do so. Your feedback is essential to help us determine the next corticosteroid interventions to be studied in this trial.

Please click [here](#) to access the survey. Completing it will take only 3–4 minutes.

The Ecraid REMAP-CAP team wishes you a happy holiday season!

For live EU region enrolment data click [here](#)

World

- [244 sites](#)
- [15.744 unique patients](#)
- [10.503 COVID-19 patients](#)
- [26.802 randomisations](#)

European region

- [101 sites](#)
- [8.609 unique patients](#)
- [6.865 COVID-19 patients](#)
- [15.783 randomisations](#)

Let's connect



The ECRAID-Base project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 965313



ecraid

ecraid
Base